LivaNova PLC ( LIVN ) NASDAQ Global Select

Cena: 45.41 ( 0.53% )

Aktualizacja 06-20 21:54
NASDAQ Global Select
Branża: Medical - Devices
Statystyki
Dywidendy
Rekomendacje
Wyceny
Wskaźniki
Analiza techniczna

Notowania:

Informacje o spółce:
Sektor: Zdrowie
Branża: Medical - Devices
Zatrudnienie: 2 900
Giełda: NASDAQ Global Select
Ilość akcji w obrocie: 100%
Ilość akcji: 53 870 800
Debiut giełdowy: 2015-10-19
WWW: https://www.livanova.com
CEO: Mr. Vladimir A. Makatsaria
Adres: 20 Eastbourne Terrace
Siedziba: W2 6LG London
ISIN: GB00BYMT0J19
Opis firmy:

Livanova PLC, firma zajmująca się urządzeniami medycznymi, projektuje, rozwija, produkuje i sprzedaje rozwiązania terapeutyczne na całym świecie. Działa przez trzy segmenty: krążeniowo -oddechowe, neuromodulacja i zaawansowane wsparcie krążenia. Segment krążeniowy rozwija się, produkuje i sprzedaje produkty krążeniowo-oddechowe, w tym utleniczki, maszyny do płuc serca, systemy autotransfusion, systemy rur perfuzyjnych, kaniulki, Connect i inne powiązane produkty. Segment neuromodulacyjny projektuje, rozwija i sprzedaje system terapii VNS, wszczepialne urządzenie, które zapewnia terapię stymulacji nerwu błędnego (VNS) w leczeniu padaczki odpornej na leki, trudną do leczenia depresji i niedrożności snu. Jest również zaangażowany w rozwój i badania kliniczne systemu vitaria w leczeniu niewydolności serca przez VNS. Zaawansowany segment wsparcia krążenia rozwija się, produkuje i sprzedaje tymczasowe produkty podtrzymujące, takie jak rozwiązania wsparcia krążeniowo -płucne i oddechowe. Firma obsługuje perfuzyści, neurologów, neurochirurgów i innych lekarzy, a także szpitali, innych instytucji medycznych i świadczeniodawców. Sprzedaje swoje produkty za pośrednictwem bezpośrednich przedstawicieli handlowych i niezależnych dystrybutorów. Firma przeprowadza współpracę badawczą z Verily w celu zdobycia klinicznych biomarkerów depresji. Livanova plc został założony w 1987 roku i ma siedzibę w Londynie w Wielkiej Brytanii.

Wskaźniki finansowe
Kapitalizacja (USD) 2 476 012 037
Aktywa: 2 521 958 000
Cena: 45.41
Wskaźnik Altman Z-Score: 1.7
Słaby (wysokie ryzyko bankructwa)
Dywidenda: 0
P/E: -11.2
Ilość akcji w obrocie: 100%
Średni wolumen: 781 737
Ilość akcji 54 525 700
Wskaźniki finansowe
Przychody TTM 1 241 707 000
Zobowiązania: 1 211 914 000
Przedział 52 tyg.: 32.48 - 57.35
Piotroski F-Score: 7
Silny (dobra jakość finansowa)
EPS: -4.1
P/E branży: 26.8
Beta: 1.009
Raport okresowy: 2025-07-29
WWW: https://www.livanova.com
Zarząd
Imie i Nazwisko Stanowisko Wynagrodzenie Rok urodzenia
Ms. Trui Hebbelinck Chief Human Resources Officer 895 046 1973
Mr. Alex Shvartsburg Chief Financial Officer 1 202 899 1970
Mr. Michael D. Hutchinson Senior Vice President, Chief Legal Officer & Company Secretary 1 092 187 1971
Mr. Paul R. Buckman President of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement 0 1956
Mr. Matthew Joseph Dodds III Senior Vice President of Corporate Development & IT 0 0
Ahmet Tezel Ph.D. Chief Innovation Officer 0 0
Mr. Vladimir A. Makatsaria Chief Executive Officer & Director 0 1973
Ms. Stephanie Bolton President of Global Epilepsy 0 1982
Lindsey Little Senior Director of Investor Relations 0 0
Deanna Wilke Vice President of Corporate Communications 0 0
Wiadomości dla LivaNova PLC
Tytuł Treść Źródło Aktualizacja Link
LivaNova to Present at the Jefferies Global Healthcare Conference LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The presentation will take place Thurs., June 5, at 3:10 p.m. Eastern Time. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should log on. businesswire.com 2025-05-15 12:00:00 Czytaj oryginał (ang.)
LivaNova PLC (LIVN) Q1 2025 Earnings Call Transcript LivaNova PLC (NASDAQ:LIVN ) Q1 2025 Earnings Conference Call May 7, 2025 8:00 AM ET Company Participants Briana Gotlin – Vice President, Investor Relations Vladimir Makatsaria – Chief Executive Officer Ahmet Tezel – Chief Innovation Officer Alex Shvartsburg – Chief Financial Officer Stephanie Bolton – President, Global Epilepsy Conference Call Participants Rick Wise – Stifel David Roman – Goldman Sachs Adam Maeder – Piper Sandler Mike Sarcone – Jefferies Mike Matson – Needham & Co. David Rescott – Baird Michael Polark – Wolfe Research Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC First Quarter 2025 Earnings Conference Call. My name is Emily, and I'll be coordinating your call today. seekingalpha.com 2025-05-11 06:56:52 Czytaj oryginał (ang.)
LivaNova (LIVN) Q1 Earnings and Revenues Surpass Estimates LivaNova (LIVN) came out with quarterly earnings of $0.88 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.73 per share a year ago. zacks.com 2025-05-07 12:15:41 Czytaj oryginał (ang.)
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance. Financial Summary and Highlights(1) First-quarter revenue of $316.9 million increased 7.4% on a reported basis, 8.9% on a constant-currency basis, and 10.4% on an organic basis as compared to the prior-year period First-quarter U.S. GAAP diluted loss per share of $6.01, impacted by recording SNIA. businesswire.com 2025-05-07 10:00:00 Czytaj oryginał (ang.)
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy LONDON--(BUSINESS WIRE)-- #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the aura6000™ System for the treatment of moderate to severe obstructive sleep apnea (OSA). At 12 months of therapy, the treatment arm responder rate was 65% with responders defined as those who realized at least a 50% improvement from the baseline apnea-hypopnea index (AHI) and an A. businesswire.com 2025-05-07 09:45:00 Czytaj oryginał (ang.)
LivaNova to Announce First-Quarter 2025 Results LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC will host a conference call to discuss its first-quarter 2025 results on Wed., May 7, 2025, at 1 p.m. London time (8 a.m. Eastern Time). businesswire.com 2025-03-26 10:00:00 Czytaj oryginał (ang.)
LivaNova (LIVN) Tops Q4 Earnings Estimates LivaNova (LIVN) came out with quarterly earnings of $0.81 per share, beating the Zacks Consensus Estimate of $0.80 per share. This compares to earnings of $0.87 per share a year ago. zacks.com 2025-02-25 10:10:24 Czytaj oryginał (ang.)
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance. businesswire.com 2025-02-25 08:00:00 Czytaj oryginał (ang.)
LivaNova to Present at the Barclays Global Healthcare Conference LONDON--(BUSINESS WIRE)--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global Healthcare Conference in Miami, Florida. The presentation will take place at 2:00 p.m. Eastern Time on Tuesday, March 11. The discussion will be available to all interested parties who register to attend the webcast, which is accessible via www.livanova.com/events. Listeners should. businesswire.com 2025-02-21 11:00:00 Czytaj oryginał (ang.)
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results LONDON--(BUSINESS WIRE)-- #LIVN--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its fourth-quarter and full-year 2024 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to rec. businesswire.com 2025-01-21 11:00:00 Czytaj oryginał (ang.)
5 Beaten-Down MedTech Stocks Set to Rebound in 2025 Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape. zacks.com 2024-12-30 11:25:28 Czytaj oryginał (ang.)
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. businesswire.com 2024-12-18 10:30:00 Czytaj oryginał (ang.)
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles. businesswire.com 2024-12-05 11:00:00 Czytaj oryginał (ang.)
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know The mean of analysts' price targets for LivaNova (LIVN) points to a 37.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. zacks.com 2024-11-28 13:01:24 Czytaj oryginał (ang.)
LivaNova's OSPREY Sleep Apnea Trail on aura6000 Meets Primary Endpoint LIVN's aura6000 significantly increases responder rates. The device also reduces AHI and ODI levels. zacks.com 2024-11-18 10:45:23 Czytaj oryginał (ang.)
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. businesswire.com 2024-11-11 18:05:00 Czytaj oryginał (ang.)
LivaNova (LIVN) Upgraded to Strong Buy: What Does It Mean for the Stock? LivaNova (LIVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). zacks.com 2024-11-07 15:00:57 Czytaj oryginał (ang.)
How Much Upside is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2% The consensus price target hints at a 38.2% upside potential for LivaNova (LIVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. zacks.com 2024-11-07 13:00:47 Czytaj oryginał (ang.)
Best Momentum Stocks to Buy for November 7th KRUS, FTDR and LIVN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 7, 2024. zacks.com 2024-11-07 13:00:39 Czytaj oryginał (ang.)
New Strong Buy Stocks for November 7th MCO, EBS, LIVN, FTDR and KRUS have been added to the Zacks Rank #1 (Strong Buy) List on November 7, 2024. zacks.com 2024-11-07 08:31:12 Czytaj oryginał (ang.)
Best Value Stocks to Buy for November 7th JWN and LIVN made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 7, 2024. zacks.com 2024-11-07 07:40:36 Czytaj oryginał (ang.)
LivaNova PLC (LIVN) Q3 2024 Earnings Call Transcript LivaNova PLC (NASDAQ:LIVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Matthew Dodds - Senior Vice President-Corporate Development & IT Vladimir Makatsaria - Chief Executive Officer Ahmet Tezel - Chief Innovation Officer Alex Shvartsburg - Chief Financial Officer Stephanie Bolton - President, Global Epilepsy Conference Call Participants David Roman - Goldman Sachs Rick Wise - Stifel David Rescott - Baird Michael Pollack - Wolfe Research Adam Maeder - Piper Sandler Anthony Petrone - Mizuho Mike Matson - Needham & Company Matt Miksic - Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Third Quarter 2024 Earnings Conference Call. My name is Lydia, and I'll be your operator today. seekingalpha.com 2024-10-30 16:30:24 Czytaj oryginał (ang.)
LivaNova (LIVN) Tops Q3 Earnings and Revenue Estimates LivaNova (LIVN) came out with quarterly earnings of $0.90 per share, beating the Zacks Consensus Estimate of $0.71 per share. This compares to earnings of $0.73 per share a year ago. zacks.com 2024-10-30 10:15:25 Czytaj oryginał (ang.)
LivaNova Reports Third-Quarter 2024 Results LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today reported results for the quarter ended September 30, 2024 and raised full-year 2024 guidance. businesswire.com 2024-10-30 08:00:00 Czytaj oryginał (ang.)
LivaNova: Economics Should Start Making Sustained Improvements LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth. seekingalpha.com 2024-10-18 07:45:53 Czytaj oryginał (ang.)
LivaNova's New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts Shares of LivaNova Plc LIVN Tuesday climbed along with several other big stocks. benzinga.com 2024-10-04 15:59:44 Czytaj oryginał (ang.)
LivaNova PLC (LIVN) Q2 2024 Earnings Call Transcript LivaNova PLC (NASDAQ:LIVN ) Q2 2024 Earnings Conference Call July 31, 2024 8:00 AM ET Company Participants Matthew Dodds – Senior Vice President-Corporate Development and IT Vladimir Makatsaria – Chief Executive Officer Alex Shvartsburg – Chief Financial Officer Ahmet Tezel – Chief Innovation Officer Conference Call Participants Rick Wise – Stifel Mike Sarcone – Jefferies Michael Polark – Wolfe Research Adam Maeder – Piper Sandler Anthony Petrone – Mizuho Group Mike Matson – Needham & Company David Rescott – Baird Matt Miksic – Barclays Operator Good day, ladies and gentlemen, and welcome to the LivaNova PLC Second Quarter 2024 Earnings Conference Call. My name is Emily, and I'll be moderating your call today. seekingalpha.com 2024-07-31 17:57:09 Czytaj oryginał (ang.)
LivaNova (LIVN) Beats Q2 Earnings and Revenue Estimates LivaNova (LIVN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.79 per share. This compares to earnings of $0.78 per share a year ago. zacks.com 2024-07-31 12:10:37 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980. globenewswire.com 2024-07-26 16:19:00 Czytaj oryginał (ang.)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC ("LivaNova" or the "Company") (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com 2024-07-25 00:57:00 Czytaj oryginał (ang.)